What Ozempic Is Actually Approved For
Ozempic is FDA-approved for adults with type 2 diabetes — not for weight loss. According to the FDA prescribing information (DailyMed, 2025), Ozempic (semaglutide) injection is indicated for three things: as an adjunct to diet and exercise to improve blood sugar (glycemic control) in adults with type 2 diabetes; to reduce the risk of major adverse cardiovascular events (cardiovascular death, heart attack, stroke) in adults who have type 2 diabetes and established cardiovascular disease; and to reduce the risk of kidney-function decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
Notice what is not on that list: weight loss or weight management. Ozempic was first approved in 2017. People in Ozempic's diabetes trials did lose some weight as a secondary effect, but weight loss is not an approved use of the drug. That distinction is the whole reason the phrase 'off-label' keeps coming up when non-diabetic people ask about Ozempic.
Ozempic's maximum approved dose is 2.0 mg once weekly, stepped up gradually from 0.25 mg. This dose ceiling becomes relevant later, because the weight-loss version of the same molecule is approved to go a step higher.
'Off-Label' Explained: Legal, Common, but Not the Same as Approved
Prescribing Ozempic for weight loss in a person without type 2 diabetes is off-label use — meaning a clinician prescribes an FDA-approved drug for a purpose other than what its label authorizes. Off-label prescribing is legal and widespread across medicine. The U.S. Supreme Court has recognized off-label use by physicians as a legitimate and important part of medical practice, and Section 396 of the Federal Food, Drug, and Cosmetic Act (21 USC 396) expressly protects a clinician's authority to prescribe an approved drug for a condition not on the label, within a legitimate provider-patient relationship (Health Law Alliance, 2026).
There are two important limits to understand. First, the protection covers the prescriber, not the manufacturer. Novo Nordisk cannot legally market or promote Ozempic for weight loss — which is exactly why its weight-loss programs and materials point to Wegovy, not Ozempic. Second, 'legal' is not the same as 'covered' or 'always appropriate.' A clinician is still accountable to the standard of care and state medical-board rules, and an insurer has no obligation to pay for an off-label use.
In short: off-label Ozempic for weight loss is not fringe or shady, but it is a workaround. When an FDA-approved equivalent for the exact goal already exists, many clinicians consider it more straightforward to prescribe that instead.
Wegovy Is the Same Molecule, Approved for Weight Loss
Wegovy and Ozempic are the same active drug — semaglutide — made by the same manufacturer. The difference is regulatory and dose-related, not chemical. Wegovy was FDA-approved in 2021 specifically for chronic weight management: it's indicated, alongside a reduced-calorie diet and increased activity, for adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. It's also approved for adolescents 12 and older with obesity (StatPearls/NCBI, 2024; UCHealth, 2026).
Two practical differences matter. Wegovy is dosed higher — up to 2.4 mg once weekly, versus Ozempic's 2.0 mg ceiling — and Wegovy's evidence base comes from trials run in people with obesity, many without diabetes. As an endocrinologist quoted by UCHealth put it, 'They are just prescribed under different names with slightly different doses and different indications. The drug product itself is the same.'
This is the core reason a clinician evaluating a non-diabetic patient for weight loss often chooses Wegovy over off-label Ozempic: it's the on-label choice, it reaches a higher dose, and it's backed by weight-management trials in the relevant population. A separate FDA-approved option, Zepbound (tirzepatide), works on two gut-hormone receptors and produced even larger average weight loss in its trials. Which option — if any — fits a given person is a clinical decision.
What the Trials Show in People Without Diabetes
The headline weight-loss numbers you see for semaglutide come from Wegovy's trials, not Ozempic's. In STEP-1 (Wilding and colleagues, New England Journal of Medicine, 2021), 1,961 adults with overweight or obesity and without diabetes received either semaglutide 2.4 mg (Wegovy) or placebo for 68 weeks, plus lifestyle counseling. Average body weight fell about 14.9% with semaglutide versus 2.4% with placebo. About 86% of the semaglutide group lost at least 5% of their body weight, 69% lost at least 10%, and 50% lost at least 15%.
On safety in non-diabetic adults, the SELECT trial (Lincoff and colleagues, NEJM, 2023) followed more than 17,000 adults with overweight or obesity and established cardiovascular disease — but without diabetes — on semaglutide 2.4 mg, and found a roughly 20% reduction in major cardiovascular events over a mean follow-up of about 3.3 years (39.8 months). SELECT used the 2.4 mg dose (higher than Ozempic's 2.0 mg maximum), which gives clinicians reassurance that semaglutide's safety profile extends to the non-diabetic population.
One nuance worth stating plainly: the 14.9% figure is the Wegovy 2.4 mg result. Ozempic at its 2.0 mg maximum has no equivalent large obesity trial in non-diabetic people, so quoting '15% weight loss' for off-label Ozempic slightly overstates what its own dose was studied to do. These trial numbers describe study populations, not a prediction for any individual.
Insurance: Why Off-Label Ozempic Usually Isn't Covered
If you don't have type 2 diabetes, insurance is the practical wall most people hit. Legal permission to prescribe off-label does not obligate any payer to cover it. Most commercial and Medicare Part D plans require the on-label indication — a type 2 diabetes diagnosis — to cover Ozempic, and off-label weight-loss use in a non-diabetic patient is rarely a coverage-recognized off-label use (Health Law Alliance, 2026).
Separately, many plans historically excluded weight-loss medications altogether, or require prior authorization and step therapy even for Wegovy. So a non-diabetic person can run into two coverage problems at once: Ozempic isn't covered because there's no diabetes diagnosis, and Wegovy — though on-label — may still be excluded or gated by the plan's weight-loss-drug rules. Coverage varies widely by plan and changes frequently, so the only reliable answer is to check your specific benefits.
Using a manufacturer self-pay program or paying cash does not count toward your deductible or out-of-pocket maximum, per NovoCare and LillyDirect terms. That matters if you also have other medical costs during the year.
The Cash and Telehealth Route
Because coverage is often the obstacle, many people without diabetes go the cash or telehealth route — and importantly, they usually end up on an FDA-approved weight-loss drug (Wegovy or Zepbound) rather than off-label Ozempic, because the manufacturers' self-pay programs are built around the weight-approved products.
Manufacturer self-pay: Novo Nordisk's NovoCare sells Wegovy self-pay at around $199/month for the first two starter fills, then Wegovy runs about $349/month at standard doses (2026 program terms). Lilly's LillyDirect offers Zepbound self-pay roughly $299–$699/month depending on dose and on refilling within 45 days. Brand list ('sticker') prices without any program are far higher — roughly $968 for Ozempic and $1,349 for Wegovy per month (manufacturer/FormBlends data, July 2026). Prices change often; verify current numbers before relying on them.
Telehealth platforms (such as Ro, Hims, and others) add a prescriber visit, dosing support, and sometimes insurance help for a monthly membership on top of the drug. Some telehealth brands also advertise compounded semaglutide or tirzepatide at lower prices. Be aware that compounded GLP-1s are not FDA-approved finished drugs — they're prepared by state-licensed pharmacies against an individual prescription, they haven't gone through the FDA's approval process for that product, and provider review is required. If you go this route, use a licensed U.S. provider and a state-licensed pharmacy. You can compare vetted GLP-1 telehealth options through our provider comparisons.
Safety Basics for Non-Diabetic Adults
Semaglutide's most common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, and abdominal pain — which are usually mild to moderate and tend to ease over time as the dose is increased slowly (Ozempic prescribing information, DailyMed 2025). In STEP-1, gastrointestinal events were the main reason a small share of participants (about 4.5%) stopped semaglutide.
Semaglutide carries a boxed warning about the risk of thyroid C-cell tumors seen in rodent studies; it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. It's also not recommended in pregnancy. These are label-level facts, not personalized guidance — a clinician screens for these before prescribing, and only a clinician can decide whether any GLP-1 is safe for you.
One more honest point on the broader comparison: GLP-1 medicines generally produce more weight loss in trials than older options like Contrave or phentermine-based drugs, but 'more weight loss on average' is not the same as 'better for you.' The right choice depends on your medical history, other conditions, tolerance for side effects, cost, and coverage — and that's a decision for you and a licensed clinician, not a web page.